ETFMG Treatments, Testing and Advancements ETF (GERM): Price and Financial Metrics ETF

ETFMG Treatments, Testing and Advancements ETF (GERM): $19.16

0.06 (-0.29%)

POWR Rating

Component Grades

Buy & Hold

NR

Peer

NR

Add GERM to Watchlist
Sign Up

Category: Health & Biotech ETFs

Category

D

Ranked

Unranked

in category

GERM Price/Volume Stats - 7 Best ETFs for the NEXT Bull Market

Current price $19.16 52-week high $20.20
Prev. close $19.21 52-week low $15.67
Day low $19.16 Volume 4,800
Day high $19.28 Avg. volume 1,891
50-day MA $18.94 Dividend yield 1.22%
200-day MA $18.54

GERM Stock Price Chart Interactive Chart >


ETFMG Treatments, Testing and Advancements ETF (GERM) ETF Bio


The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the Prime Treatments, Testing and Advancements Index. The fund invests at least 80% of its total assets in the component securities of the index. The index tracks the performance of U.S.-listed equity securities or depositary receipts of companies that (i) perform research, development, and commercialization of treatments or vaccines for infectious diseases or (ii) engage in the research, development, manufacturing, and provision of biological tests for patients. The fund is non-diversified.

GERM ETF Info

Issuer ETF Managers Group
Expense Ratio 0.68%
Underlying Index Prime Treatments, Testing and Advancements Index
Asset Class Equity
Sector Health & Biotech ETFs
Assets Under Management (AUM) 9.67M
Net Asset Value (NAV) $19.34
Options? Yes
Total Holdings 2

GERM Top Holdings

Symbol Company % of Total
GERM ETFMG Treatments Testing and Adv ETF 0%
GERM ETFMG Treatments Testing and Adv ETF 0%
%
%
%
%
%
%
%
%

GERM Price Returns

1-mo N/A
3-mo -0.75%
6-mo 0.29%
1-year 10.01%
3-year N/A
5-year N/A
YTD -1.28%
2023 -11.56%
2022 -36.78%
2021 14.86%
2020 N/A
2019 N/A

GERM Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full GERM Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!